Although no clinical trials are testing these compounds, inhibition of TAGLN2 may be pursued as a therapeutic option for breast cancer patients expressing high levels of this gene following confirmation of the prognostic impact of the protein in breast cancer patients. The gene discussed is TAGLN2; the disease is breast cancer.